Davis Polk advised J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Leerink Swann LLC as joint book-running managers on an SEC-registered offering of 5,785,123 shares of common stock of The Medicines Company for an aggregate price to the public of approximately $175 million. The underwriters have a 30-day option to purchase up to an additional 867,768 shares. The Medicines Company’s common stock is listed on the NASDAQ Global Select Market under the trading symbol “MDCO.”
Headquartered in Parsippany, New Jersey, The Medicines Company is a global pharmaceutical company focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace.
The Davis Polk capital markets team included partner Richard D. Truesdell Jr. and associates Shane Tintle and Christopher M. Bezeg. Partner Frank J. Azzopardi and associates David R. Bauer and Bruce Rose-Innes provided intellectual property advice. The tax team included partner Michael Farber, associate Adam B. Perry, law clerk Adam Bedzow and former associate Yuliya Epifantseva. The environmental team included counsel Betty M. Huber and associate Michael Comstock. Karla A. Rivera Fortis was the legal assistant on the transaction. All members of the Davis Polk team are based in the New York office.
